These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 34602288)

  • 1. Early prediction of post-molar gestational trophoblastic neoplasia and resistance to methotrexate, based on a single serum human chorionic gonadotropin measurement.
    Hoeijmakers YM; Eysbouts YK; Massuger LFAG; Dandis R; Inthout J; van Trommel NE; Ottevanger PB; Thomas CMG; Sweep FCGJ
    Gynecol Oncol; 2021 Dec; 163(3):531-537. PubMed ID: 34602288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does a human chorionic gonadotropin level of over 20,000 IU/L four weeks after uterine evacuation for complete hydatidiform mole constitute an indication for chemotherapy for gestational trophoblastic neoplasia?
    Braga A; Biscaro A; do Amaral Giordani JM; Viggiano M; Elias KM; Berkowitz RS; Seckl MJ
    Eur J Obstet Gynecol Reprod Biol; 2018 Apr; 223():50-55. PubMed ID: 29477553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human Chorionic Gonadotropin (hCG) Regression Curve for Predicting Response to EMA/CO (Etoposide, Methotrexate, Actinomycin D, Cyclophosphamide and Vincristine) Regimen in Gestational Trophoblastic Neoplasia.
    Rattanaburi A; Boonyapipat S; Supasinth Y
    Asian Pac J Cancer Prev; 2015; 16(12):5037-41. PubMed ID: 26163637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia.
    Lybol C; Sweep FC; Harvey R; Mitchell H; Short D; Thomas CM; Ottevanger PB; Savage PM; Massuger LF; Seckl MJ
    Gynecol Oncol; 2012 Jun; 125(3):576-9. PubMed ID: 22410329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of 5-day MTX and 5-day ETP treatment results and early predictors of drug resistance to 5-day MTX in patients with post-molar low-risk gestational trophoblastic neoplasia.
    Kizaki S; Hashimoto K; Matsui H; Usui H; Shozu M
    Gynecol Oncol; 2015 Dec; 139(3):429-32. PubMed ID: 26456138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience.
    Maestá I; Nitecki R; Horowitz NS; Goldstein DP; de Freitas Segalla Moreira M; Elias KM; Berkowitz RS
    Gynecol Oncol; 2018 Jan; 148(1):161-167. PubMed ID: 29092742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gestational trophoblastic neoplasia after spontaneous human chorionic gonadotropin normalization following molar pregnancy evacuation.
    Braga A; Maestá I; Matos M; Elias KM; Rizzo J; Viggiano MG
    Gynecol Oncol; 2015 Nov; 139(2):283-7. PubMed ID: 26383828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of persistent gestational trophobalstic neoplasia: the role of hCG level and ratio in 2 weeks after evacuation of complete mole.
    Kang WD; Choi HS; Kim SM
    Gynecol Oncol; 2012 Feb; 124(2):250-3. PubMed ID: 22094931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of gestational trophoblastic neoplasia after hCG normalisation according to hydatidiform mole type.
    Schmitt C; Doret M; Massardier J; Hajri T; Schott AM; Raudrant D; Golfier F
    Gynecol Oncol; 2013 Jul; 130(1):86-9. PubMed ID: 23523617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human chorionic gonadotropin (hCG) regression normograms for patients with high-risk gestational trophoblastic neoplasia treated with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine) chemotherapy.
    Lybol C; Westerdijk K; Sweep FCGJ; Ottevanger PB; Massuger LFAG; Thomas CMG
    Ann Oncol; 2012 Nov; 23(11):2903-2906. PubMed ID: 22730100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The management of hydatidiform mole using prophylactic chemotherapy and hysterectomy for high-risk patients decreased the incidence of gestational trophoblastic neoplasia in Vietnam: a retrospective observational study.
    Yamamoto E; Trinh TD; Sekiya Y; Tamakoshi K; Nguyen XP; Nishino K; Niimi K; Kotani T; Kajiyama H; Shibata K; Le QT; Kikkawa F
    Nagoya J Med Sci; 2020 May; 82(2):183-191. PubMed ID: 32581399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gestational trophoblastic neoplasia after human chorionic gonadotropin normalization in a retrospective cohort of 7761 patients in France.
    Descargues P; Hajri T; Massardier J; Lotz JP; Devouassoux-Shisheboran M; Allias Montmayeur F; You B; Golfier F; Bolze PA
    Am J Obstet Gynecol; 2021 Oct; 225(4):401.e1-401.e9. PubMed ID: 34019886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for second-line dactinomycin failure after methotrexate treatment for low-risk gestational trophoblastic neoplasia: a retrospective study.
    Hoeijmakers YM; Sweep F; Lok C; Ottevanger PB
    BJOG; 2020 Aug; 127(9):1139-1145. PubMed ID: 32141676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early prediction of treatment resistance in low-risk gestational trophoblastic neoplasia using population kinetic modelling of hCG measurements.
    You B; Harvey R; Henin E; Mitchell H; Golfier F; Savage PM; Tod M; Wilbaux M; Freyer G; Seckl MJ
    Br J Cancer; 2013 May; 108(9):1810-6. PubMed ID: 23591194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of previous cesarean section (C/S) on the risk for post-molar gestational trophoblastic neoplasia (GTN).
    Cho HW; Ouh YT; Min KJ; Lee NW; Lee S; Song JY; Hong JH; Lee JK
    Gynecol Oncol; 2020 Mar; 156(3):606-610. PubMed ID: 31954533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating methotrexate treatment in patients with low-risk postmolar gestational trophoblastic neoplasia.
    Growdon WB; Wolfberg AJ; Goldstein DP; Feltmate CM; Chinchilla ME; Lieberman ES; Berkowitz RS
    Gynecol Oncol; 2009 Feb; 112(2):353-7. PubMed ID: 19059633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increasing the human chorionic gonadotrophin cut-off to ≤1000 IU/l for starting actinomycin D in post-molar gestational trophoblastic neoplasia developing resistance to methotrexate spares more women multi-agent chemotherapy.
    Cortés-Charry R; Hennah L; Froeling FEM; Short D; Aguiar X; Tin T; Harvey R; Unsworth N; Kaur B; Savage P; Sarwar N; Seckl MJ
    ESMO Open; 2021 Jun; 6(3):100110. PubMed ID: 33845362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of an online tool for early prediction of the failure-risk in gestational trophoblastic neoplasia patients treated with methotrexate.
    Dekeister K; Bolze PA; Tod M; Tod R; Massardier J; Lotz JP; Hajri T; Colomban O; Seckl MJ; Osborne R; Freyer G; Golfier F; You B
    Cancer Chemother Pharmacol; 2020 Jul; 86(1):15-24. PubMed ID: 32500221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postmolar gestational trophoblastic neoplasia: beyond the traditional risk factors.
    Bakhtiyari M; Mirzamoradi M; Kimyaiee P; Aghaie A; Mansournia MA; Ashrafi-Vand S; Sarfjoo FS
    Fertil Steril; 2015 Sep; 104(3):649-54. PubMed ID: 26099850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gestational Trophoblastic Neoplasia After Human Chorionic Gonadotropin Normalization Following Molar Pregnancy: A Systematic Review and Meta-analysis.
    Albright BB; Shorter JM; Mastroyannis SA; Ko EM; Schreiber CA; Sonalkar S
    Obstet Gynecol; 2020 Jan; 135(1):12-23. PubMed ID: 31809433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.